LONDON – The venture capital investors in Amsterdam Molecular Therapeutics (AMT) have thrown it a €2.5 million (US$3.2 million) lifeline in the hope that will enable the company to stay solvent long enough to close a deal for its gene therapy treatment for hemophilia B.